Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common stock
-
Shares outstanding
-
9,600,143
-
Total 13F shares
-
437,052
-
Share change
-
+146,040
-
Total reported value
-
$177,030
-
Price per share
-
$0.41
-
Number of holders
-
18
-
Value change
-
+$57,424
-
Number of buys
-
11
-
Number of sells
-
6
Institutional Holders of Theriva Biologics, Inc. - Common stock (TOVX) as of Q3 2025
As of 30 Sep 2025,
Theriva Biologics, Inc. - Common stock (TOVX) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
437,052 shares.
The largest 10 holders included
Ikarian Capital, LLC, TWO SIGMA INVESTMENTS, LP, Virtu Financial LLC, JANE STREET GROUP, LLC, BOOTHBAY FUND MANAGEMENT, LLC, XTX Topco Ltd, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA ADVISERS, LP, UBS Group AG, and VANGUARD GROUP INC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.